Infliximab stopped severe gastrointestinal bleeding in Crohn's disease

Table 1 Clinical characteristics and outcomes of infliximab treatment in 2 Crohn’s disease patients with severe gastrointestinal bleeding as a flare-up disease

No.	Age(yr)	Sex	Duration of CD	Location	Current treatment	Presenting symptom	Dropped rate of Hb (g/dL)	PRBC (unit)	Characteristic of lesion	Infliximab therapy	Bleeding controlled in	Follow-up (mo)
1	11	F	2 mo	Colon	Prednisolone 35 mg/d azathioprine	GIB (1 d)	from 11 to 8 in 3 d	4	Multiple deep colonic ulcers without oozing	Infliximab 5 mg/kg (single dose)	1 d	12
2	19	F	7 mo	Ileocolon	Budesonide 9 mg/d 5-ASA	GIB (1 d)	from 12 to 10 in 3 d	1	Multiple ileal and colonic ulcers with oozing	Infliximab 5 mg/kg (d0, d10)	10 d	10

CD: Crohn’s disease; GIB: Gastrointestinal bleeding; Hb: Hemoglobin; 5-ASA: 5-aminosalicylates; PRBC: Packed red blood cell; F: Female.